Search Results
Sep 08, 2026, 09:22 ET Harmonic presenta la plataforma de inteligencia cOS SensAI para operaciones de banda ancha
operaciones, ofrecer experiencias excepcionales a sus suscriptores y diversificar sus fuentes de ingresos. Con miles de servidores vCMTS y cientos de miles de RPD desplegados globalmente, Harmonic impulsa los servicios de banda ancha de próxima generación con una fiabilidad del 99,999 %. Con un enfoque centrado
More news about: Harmonic Inc.
Sep 08, 2026, 08:00 ET North American Operators Investing Heavily in PON Equipment As Fiber Subscribers Continue to Surge, According to Dell'Oro Group
purchases to support their multi-gig service offerings.Cable operators are modernizing their networks through sustained Remote PHY Device (RPD) and Remote OLT (R-OLT) purchases, with combined revenue for those platforms jumping 63 percent Y/Y.FWA CPE unit shipments declined 12 percent
More news about: Dell'Oro Group
Sep 08, 2026, 08:00 ET Harmonic présente son tissu d'intelligence cOS SensAI pour les opérations haut débit
une expérience client exceptionnelle et de diversifier leurs sources de revenus. Avec des milliers de serveurs vCMTS et des centaines de milliers de RPD déployés dans le monde entier, Harmonic soutient les services haut débit de nouvelle génération grâce à une fiabilité de 99,999 %. Fidèle à une approche
More news about: Harmonic Inc.
Aug 07, 2026, 08:45 ET Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Duchenne Muscular Dystrophy, as well as Rare Pediatric Disease (RPD) designation for (Z)-endoxifen for the treatment of both Duchenne Muscular Dystrophy and McCune-Albright Syndrome. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a Priority Review Voucher
More news about: Atossa Therapeutics Inc
Jun 09, 2026, 07:00 ET RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
"Company"), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease (RPD) designation to opaganib for treatment of neuroblastoma (NB).
More news about: RedHill Biopharma Ltd.
May 21, 2026, 15:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD
May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rapid7, Inc. ("Rapid7" or the "Company") (NASDAQ: RPD). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 20, 2026, 16:45 ET Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
indication.Atossa has previously received Orphan Drug and Rare Pediatric Disease (RPD) designations for (Z)-endoxifen for the treatment of DMD from the FDA. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a Priority Review Voucher (PRV), which can be used
More news about: Atossa Therapeutics Inc
May 14, 2026, 23:01 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD
May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rapid7, Inc. ("Rapid7" or the "Company") (NASDAQ: RPD). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 13, 2026, 14:25 ET RAPID7 LAUNCHES CYBER GRC EARLY ACCESS PROGRAM WITH 360 ADVANCED TO BRIDGE SECURITY OPERATIONS AND COMPLIANCE FOR ORGANIZATIONS
[email protected] Rapid7Rapid7, Inc. (NASDAQ: RPD) is a global leader in AI-powered managed cybersecurity operations, trusted to advance organizations' cyber resilience. Open and extensible, the Rapid7
More news about: 360 Advanced
May 08, 2026, 08:45 ET Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Pediatric Disease (RPD) designation for (Z)-endoxifen for the treatment of DMD.Atossa Therapeutics Received FDA RPD Designation for (Z)-Endoxifen for McCune-Albright Syndrome - In early May 2026, Atossa announced that the FDA had granted RPD for (Z)-Endoxifen
More news about: Atossa Therapeutics Inc
May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD
May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rapid7, Inc. ("Rapid7" or the "Company") (NASDAQ: RPD). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 04, 2026, 08:30 ET Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a
More news about: Atossa Therapeutics Inc
Apr 10, 2026, 11:30 ET Emerging AI-Driven Threats Prompt Renewed Focus on Enterprise Cybersecurity
Secure Encryption Corp. (CSE: QSE) (OTCQB: QSEGF) (FSE: VN8), SentinelOne (NYSE: S), Elastic (NYSE: ESTC), Rapid7 (NASDAQ: RPD), and Broadcom (NASDAQ: AVGO).
More news about: Equity Insider
Mar 25, 2026, 17:30 ET Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
In December 2025, Atossa announced that the U.S. Food and Drug Administration ("FDA") granted Rare Pediatric Disease ("RPD") designation to (Z)-endoxifen for the treatment of DMD. RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect
More news about: Atossa Therapeutics Inc
Mar 11, 2026, 10:00 ET Verve Medical Treats First Patient in Landmark U.S. Pilot Trial for Uncontrolled Hypertension, Advancing Momentum from Breakthrough TUSK Results
understanding of blood pressure regulation and its relationship with renal function. The RPD Pilot trial is enrolling 60 patients across 10 U.S. clinical sites, with participants randomized to receive either RPD therapy or a sham procedure to ensure rigor and objectivity. "Based on prior
More news about: Verve Medical
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
with DM1. ATX-01 has received Orphan Drug Designation for ATX-01 in DM1 from the US FDA and European authorities, as well as Rare Pediatric Disease (RPD) Designation from the FDA. About ARTHEx Biotech ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed
More news about: ARTHEx Biotech
Feb 05, 2026, 08:30 ET Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a
More news about: Atossa Therapeutics Inc
Jan 26, 2026, 08:30 ET Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II
The FDA grants RPD designation for serious or life-threatening diseases that primarily affect children 18 years old or younger and affect fewer than 200,000 people nationwide. RPD designation allows recipient companies, upon approval of their designated
More news about: Immusoft
Jan 22, 2026, 10:38 ET The Security Reset: Why Protecting Infrastructure is Driving a New Growth Cycle
Encryption Corp. (QSE) (CSE: QSE) (OTCQB: QSEGF) (FSE: VN8), Parsons Corporation (NYSE: PSN), F5 (NASDAQ: FFIV), Rapid7 (NASDAQ: RPD), and Impinj (NASDAQ: PI).
More news about: USA News Group
Jan 08, 2026, 12:40 ET The $190B Data Lockdown: Why 'Sovereign Tech' is the Next Massive Wealth Transfer
QSEGF) (FSE: VN8), Elastic (NYSE: ESTC), SentinelOne, Inc. (NYSE: S), Nutanix (NASDAQ: NTNX), and Rapid7, Inc. (NASDAQ: RPD).
More news about: Equity Insider
Dec 11, 2025, 08:00 ET Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a
More news about: Atossa Therapeutics Inc
Dec 04, 2025, 12:54 ET America's Rare Children Need Congress to Act: NORD Urges Swift Reauthorization of Proven Rare Pediatric Disease Voucher Program
/PRNewswire/ -- The National Organization for Rare Disorders (NORD®) today urged Congress to reauthorize the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program by year-end, warning that continued delay threatens the future of innovation for children with rare diseases.
More news about: National Organization for Rare Disorders (NORD®)
Dec 01, 2025, 08:00 ET Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
carcinoma (LG-UTUC, SURF303) and potentially future mUC clinical trials. The FDA has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to dabogratinib for the treatment of achondroplasia.Please visit the
More news about: Tyra Biosciences
Nov 05, 2025, 16:05 ET Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
urothelial carcinoma (SURF303) and potentially future mUC clinical trials. The FDA has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to dabogratinib for the treatment of achondroplasia. BEACH301 is a Phase 2, multicenter, open-label, dose-escalation/dose-expansion
More news about: Tyra Biosciences
Sep 17, 2025, 03:00 ET ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
DM1. ATX-01 has received Orphan Drug Designation for ATX-01 in DM1 from the US FDA and European authorities, as well as Rare Pediatric Disease (RPD) Designation from the FDA. About ARTHEx Biotech ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed
More news about: ARTHEx Biotech